Cited 5 times in
The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김주항 | - |
dc.contributor.author | 조병철 | - |
dc.date.accessioned | 2015-04-23T16:20:18Z | - |
dc.date.available | 2015-04-23T16:20:18Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/100402 | - |
dc.description.abstract | The strategies of incorporating monoclonal antibodies (MoABs) have now proved efficacy in the first-line treatment of advanced non-small cell lung cancer (NSCLC). These include targeting the vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR). Bevacizumab is a MoAB targeting the vascular endothelial growth factor (VEGF), an important mediator of new blood vessel formation. Cetuximab is a MoAB directed at EGFR. Binding cetuximab to EGFR blocks signal transduction and promotes receptor internalization and degradation. In this review, we present current data of bevacizumab and cetuximab for the first line treatment of advanced NSCLC. We also refer to their potential for Asian patients with advanced NSCLC in the first-line setting. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1~8 | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Antibodies, Monoclonal/therapeutic use* | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use* | - |
dc.subject.MESH | Asian Continental Ancestry Group | - |
dc.subject.MESH | Bevacizumab | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/drug therapy* | - |
dc.subject.MESH | Cetuximab | - |
dc.subject.MESH | Humans | - |
dc.title | The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Byoung Chul Cho | - |
dc.contributor.googleauthor | Joo Hang Kim | - |
dc.contributor.googleauthor | Ross A Soo | - |
dc.contributor.googleauthor | Chih-Hsin Yang | - |
dc.identifier.doi | 10.3349/ymj.2010.51.1.1 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00945 | - |
dc.contributor.localId | A03822 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 20046507 | - |
dc.subject.keyword | Non-small cell lung cancer | - |
dc.subject.keyword | bevacizumab | - |
dc.subject.keyword | cetuximab | - |
dc.subject.keyword | chemotherapy | - |
dc.subject.keyword | monoclonal antibody | - |
dc.contributor.alternativeName | Kim, Joo Hang | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | Kim, Joo Hang | - |
dc.contributor.affiliatedAuthor | Cho, Byoung Chul | - |
dc.citation.volume | 51 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 8 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.51(1) : 1-8, 2010 | - |
dc.identifier.rimsid | 36465 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.